The University Hospital

Prof. Dr. med. Judith Feucht

Prof. Dr. med. Judith Feucht

W2 Professorship for "Cellular Immunotherapies in Cancer"

Cluster of Excellence iFIT (EXC2180) and University Children's Hospital Tübingen

Contact

E-mail address: judith.feucht@med.uni-tuebingen.de

Clinic / Institute / Center

  • since 09/2023: W2 Professorship "Cellular Immunotherapies in cancer"
  • since 09/2020: Junior research group leader, Cluster of Excellence 2180 ("iFIT")
  • 2015-2020: Postdoctoral Research Fellow, Michel Sadelain Lab, Center for Cell Engineering, MSKCC, New York, USA
  • 2012-2015: Physician scientist in the group of Prof. Feuchtinger, University Children's Hospital Tübingen
  • CARsen: Senolytic CAR T cells as novel therapeutic concept for solid tumors and senescence-associated diseases

    ERC Starting Grant

    Duration: 60 months

    Amount of funding:

  • since 09/2023W2 Professorship "Cellular Immunotherapies in Cancer" and physician, Cluster of Excellence iFIT (EXC2180), Tübingen Children's Hospital
  • 09/2020 - 09/2023Research group leader "Cellular Therapies", Cluster of Excellence iFIT (EXC2180) and physician, Tübingen Children's Hospital
  • 09/2015 – 09/2020Postdoctoral Research Fellow, Michel Sadelain Lab, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, USA
  • 09/2011 – 09/2015Resident physician in pediatrics, University Hospital Tübingen
  • 2011M.S. thesis and license to practice medicine, University Hospital Tübingen
  • 2005-2011Studies of human medicine at the University of Tübingen; stays abroad in Sydney and Gabon
  • 2022: Württemberg Cancer Award (Dres. Bayer Foundation)
  • 2022: Curious Mind Award, Life Science (Manager Magazin and Merck)
  • 07/2020: ERC Starting Grant "ERC-2020-STG"
  • 09/2019: Kind Philipp Prize
  • 01/2017: Erna Brunner Prize
  • 07/2016 - 07/2018: Scholarship of the German Research Foundation (DFG)
  • 09/2015 - 07/2016: Research scholarship from the Care-for-Rare Foundation
  • 07/2013 - 04/2014: Fellowship of the German Center for Infection Research (DZIF)
  • Bucher P, Feucht J. 2023. LINKing signaling domains to enhance CAR T cells. Nature Cancer. Apr;4(4):447-449.
  • Jain N*, Zhao Z*, Feucht J, Koche R, Iyer A, Dobrin A, Mansilla-Soto J, Yang J, Zhan Y, Lopez M, Gunset G, Sadelain M. 2023. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature 10.1038/s41586-022-05692-z
  • Amor C*, Feucht J*, Leibold J*, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, Piersigilli A, Sadelain M, Lowe SW. Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 583(7814):127-132, 2020.
  • Feucht J*, Sun J*, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. Callibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med, 25:82-88, 2019.
  • Feucht J, Sadelain M. Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors. IOTECH, 2020.
  • Feucht J, Abou-El-Enein M. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies. Mol Ther. 2020 Oct 7;28(10):2108-2110, 2020.
  • Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J, Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood, 125(12):1986-94, 2015.
  • Publications